{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:43:05Z","timestamp":1767192185846,"version":"3.48.0"},"reference-count":43,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK, Brazil","award":["300465"],"award-info":[{"award-number":["300465"]}]},{"name":"GSK, Brazil","award":["300464"],"award-info":[{"award-number":["300464"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>As treatments for multiple myeloma (MM) evolve, there is a need for real-world insights into treatment patterns and outcomes. The treatment practices and clinical outcomes in patients with MM (TOTEMM) was a database study (2018\u20132024) of newly diagnosed transplant-ineligible patients with MM in Argentina (TOTEMM-A) and Brazil (TOTEMM-B) in a private healthcare setting. In TOTEMM-A (n = 72) and TOTEMM-B (n = 892), 37 and 92 different drug regimens were reported, respectively. In each country, treatment duration reduced across lines of therapy (LOT) (TOTEMM-A: range, 6.2\u20133.4 months; TOTEMM-B: range, 4.4\u20133.5 months); attrition rates increased across LOT (TOTEMM-A: range, 52.8\u201386.1%; TOTEMM-B: range, 41.9\u201388.0%); triplet regimens (mainly bortezomib based) were used most frequently in first-line (1L); &gt;75% relapsed within 12 months, regardless of the drug prescribed; over 90% of relapses occurred between 1L and second-line, and up to half of patients were rechallenged with the same drug; &gt;65% of patients experienced disease progression after 1L; and the 1- to 5-year adjusted cumulative risk of progression or death increased across LOT (TOTEMM-A: range, 47.1\u201388.5%; TOTEMM-B: range, 40.4\u201391.7%). The rapid and marked progression underscores the urgent need for novel treatments and regimens.<\/jats:p>","DOI":"10.3390\/curroncol33010016","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:08:11Z","timestamp":1767190091000},"page":"16","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Real-World Treatment Patterns and Clinical Outcomes of Multiple Myeloma in Argentina and Brazil: Insights from the TOTEMM Study in the Private Healthcare Sector"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"Vania","family":"Hungria","sequence":"first","affiliation":[{"name":"S\u00e3o Germano Clinic, 217\u2014Vila Nova Concei\u00e7\u00e3o, S\u00e3o Paulo 04537-081, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0140-9548","authenticated-orcid":false,"given":"Angelo","family":"Maiolino","sequence":"additional","affiliation":[{"name":"Instituto Oncomed de Educa\u00e7\u00e3o e Pesquisa, Rua Lopes Trov\u00e3o, 318, Rio de Janeiro 24220-071, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Filho","given":"Roberto Jose","family":"Pessoa de Magalh\u00e3es","sequence":"additional","affiliation":[{"name":"Instituto Oncomed de Educa\u00e7\u00e3o e Pesquisa, Rua Lopes Trov\u00e3o, 318, Rio de Janeiro 24220-071, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Pitombeira de Lacerda","sequence":"additional","affiliation":[{"name":"Centro de Hematologia E Oncologia (CHO), R. Alexandre D\u00f6hler, Joinville 89201-260, SC, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermina","family":"Remaggi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fundaleu, Pres. Jos\u00e9 Evaristo Uriburu 1450, Buenos Aires 1114, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Scibona","sequence":"additional","affiliation":[{"name":"Hospital Italiano de Buenos Aires, Juan Domingo Peron 4190, Buenos Aires 1199, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9179-4448","authenticated-orcid":false,"given":"Cristian","family":"Seehaus","sequence":"additional","affiliation":[{"name":"Hospital Italiano de Buenos Aires, Juan Domingo Peron 4190, Buenos Aires 1199, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Brulc","sequence":"additional","affiliation":[{"name":"Hospital Italiano de Buenos Aires, Juan Domingo Peron 4190, Buenos Aires 1199, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Savoy","sequence":"additional","affiliation":[{"name":"Hospital Italiano de Buenos Aires, Juan Domingo Peron 4190, Buenos Aires 1199, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorotea","family":"Fantl","sequence":"additional","affiliation":[{"name":"Hospital Italiano de Buenos Aires, Juan Domingo Peron 4190, Buenos Aires 1199, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8425-2066","authenticated-orcid":false,"given":"Claudia","family":"Soares","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Estrada dos Bandeirantes 8464, Jacarepagu\u00e1, Rio de Janeiro 22783-110, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Abreu","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Estrada dos Bandeirantes 8464, Jacarepagu\u00e1, Rio de Janeiro 22783-110, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Queiroz","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Estrada dos Bandeirantes 8464, Jacarepagu\u00e1, Rio de Janeiro 22783-110, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziela","family":"Bernardino","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Estrada dos Bandeirantes 8464, Jacarepagu\u00e1, Rio de Janeiro 22783-110, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Straus","family":"Tanaka","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Estrada dos Bandeirantes 8464, Jacarepagu\u00e1, Rio de Janeiro 22783-110, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Carrizo","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Centro Empresarial Libertador, Av. Del Libertador 7208, Buenos Aires 1429, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ventura A.","family":"Simonovich","sequence":"additional","affiliation":[{"name":"Hospital Italiano de Buenos Aires, Juan Domingo Peron 4190, Buenos Aires 1199, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tais","family":"Bertoldo Teixeira Fernandes","sequence":"additional","affiliation":[{"name":"Orizon, Alameda Tocantins, 822 Barueri, S\u00e3o Paulo 06455-020, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhumika","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, 23 Rochester Park, Singapore 139234, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Padala, S.A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., and Ajebo, G.H. (2021). Epidemiology, staging, and management of multiple myeloma. Med. Sci., 9.","DOI":"10.3390\/medsci9010003"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/j.clml.2018.06.018","article-title":"Multiple myeloma treatment in real-world clinical practice: Results of a prospective, multinational, noninterventional study","volume":"18","author":"Mohty","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1200\/OP-24-00752","article-title":"Novel Treatment Options for Multiple Myeloma","volume":"21","author":"Portuguese","year":"2025","journal-title":"JCO Oncol. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Fonseca, R., Usmani, S.Z., Mehra, M., Slavcev, M., He, J., Cote, S., Lam, A., Ukropec, J., Maiese, E.M., and Nair, S. (2020). Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07503-y"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/jha2.905","article-title":"Multiple myeloma in Latin America: A systematic review","volume":"5","author":"Blunk","year":"2024","journal-title":"EJHaem"},{"key":"ref_7","unstructured":"Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2025, September 18). Argentina. Available online: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/32-argentina-fact-sheet.pdf."},{"key":"ref_8","unstructured":"Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2025, September 18). Brazil. Available online: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/76-brazil-fact-sheet.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN Guidelines\u00ae insights: Multiple myeloma, version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/bloodadvances.2024013838","article-title":"Health care systems as determinants of outcomes in multiple myeloma: Final results from the Latin American MYLACRE study","volume":"9","author":"Hungria","year":"2025","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/1758-5899.12267","article-title":"Health care organization and delivery in Argentina: A case of fragmentation, inefficiency and inequality","volume":"8","author":"Novick","year":"2017","journal-title":"Global Policy"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Silva, B., Hens, N., Gusso, G., Lagaert, S., Macinko, J., and Willems, S. (2022). Dual use of public and private health care services in Brazil. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19031829"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12939-020-01168-6","article-title":"Need and inequality in the use of health care services in a fragmented and decentralized health system: Evidence for Argentina","volume":"19","author":"Palacios","year":"2020","journal-title":"Int. J. Equity Health"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/23288604.2018.1477537","article-title":"Making universal health care effective in Argentina: A blueprint for reform","volume":"4","author":"Rubinstein","year":"2018","journal-title":"Health Syst. Reform."},{"key":"ref_16","unstructured":"Cataife, G., and Courtemanche, C. (2025, September 18). Is Universal Health Care in Brazil Really Universal?. Available online: https:\/\/ssrn.com\/abstract=1690662."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"PA879","DOI":"10.1016\/j.jval.2017.08.2601","article-title":"High-cost oncology drugs in Brazil and Mexico: Access differences between the public and private settings","volume":"20","author":"Ribeiro","year":"2017","journal-title":"Value Health"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Devarakonda, S., Efebera, Y., and Sharma, N. (2021). Role of stem cell transplantation in multiple myeloma. Cancers, 13.","DOI":"10.3390\/cancers13040863"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jha2.739","article-title":"Real-world multiple myeloma front-line treatment and outcomes by transplant in the United States","volume":"4","author":"Richter","year":"2023","journal-title":"EJHaem"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11912-019-0804-4","article-title":"Management of newly diagnosed elderly multiple myeloma patients","volume":"21","author":"Braunstein","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjh.16124","article-title":"Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) observational study, 2008\u20132016","volume":"188","author":"Miguel","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/cam4.1347","article-title":"Epidemiology of multiple myeloma in 17 Latin American countries: An update","volume":"7","author":"Curado","year":"2018","journal-title":"Cancer Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00277-016-2866-9","article-title":"Observational study of multiple myeloma in Latin America","volume":"96","author":"Hungria","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"A879","DOI":"10.1016\/j.jval.2017.08.2602","article-title":"Real world data on multiple myeloma treatment patterns: First and second-line treatment in the Brazilian public health system","volume":"20","author":"Lemmer","year":"2017","journal-title":"Value Health"},{"key":"ref_25","unstructured":"Hospital Italiano de Buenos Aires (2025, September 18). Acerca del Hospital. Available online: https:\/\/www.hospitalitaliano.org.ar\/#!\/home\/hospital\/seccion\/20507."},{"key":"ref_26","unstructured":"Perles, D.C. (2025, September 18). Hospital Spotlight|Hospital Italiano: Carrying on with Its Expansion Plans. Available online: https:\/\/globalhealthintelligence.com\/ghi-analysis\/hospital-spotlight-hospital-italiano-carrying-on-with-its-expansion-plans\/."},{"key":"ref_27","unstructured":"(2025, September 18). Defending the Health. Available online: https:\/\/www.orizonbrasil.com.br\/."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"maapoc-0000004","DOI":"10.5301\/maapoc.0000004","article-title":"Access to oncology drugs in Brazil: Juggling innovation and sustainability in developing countries","volume":"1","author":"Ades","year":"2017","journal-title":"Med. Access@ Point Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.clml.2018.08.005","article-title":"Analysis of availability and access of anti-myeloma drugs and impact on the management of multiple myeloma in Latin American countries","volume":"19","author":"Crusoe","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1080\/14796694.2025.2504318","article-title":"Multiple myeloma care, treatment patterns, and treatment durations in academic and community care settings","volume":"21","author":"Boytsov","year":"2025","journal-title":"Future Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/10428194.2022.2140284","article-title":"Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: A US electronic health record database study","volume":"64","author":"Wang","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/17474086.2020.1800451","article-title":"Recent real-world treatment patterns and outcomes in US patients with relapsed\/refractory multiple myeloma","volume":"13","author":"Bruno","year":"2020","journal-title":"Expert. Rev. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.htct.2020.07.005","article-title":"Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma","volume":"43","author":"Pimenta","year":"2021","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gay, F., Zamagni, E., Cole, C.E., Scheid, C., Hultcrantz, M., Chorazy, J., Iheanacho, I., Pandey, A., Bitetti, J., and Boytsov, N. (2025). Clinical outcomes associated with anti-CD38-based retreatment in relapsed\/refractory multiple myeloma: A systematic literature review. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1550644"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: Patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.htct.2022.06.003","article-title":"Guidelines on the diagnosis and management of multiple myeloma treatment: Associa\u00e7\u00e3o Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associa\u00e7\u00e3o M\u00e9dica Brasileira\u20142022. Part I","volume":"44","author":"Maiolino","year":"2022","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_39","unstructured":"Alfonso, G., Arbelbide, J., Basquiera, A.L., Belli, C., Crisp, R., Gonzalez, J., Iastrebner, M., Kohan, D., Kornblihtt, L., and Lincango Yupanki, M. (2025, September 18). Neoplasias mielodispl\u00e1sicas y neoplasias mielodispl\u00e1sicas\/mieloproliferativas. Available online: https:\/\/sah.org.ar\/docs\/guias\/2023\/Neoplasias_Mielodisplasicas_y_Neoplasias_Mielodisplasicas_Mieloproliferativas.pdf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"8041","DOI":"10.1200\/JCO.2018.36.15_suppl.8041","article-title":"Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM registry","volume":"36","author":"Jagannath","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/ejh.13976","article-title":"Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 national healthcare database","volume":"111","author":"Leleu","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/cam4.2656","article-title":"Connect MM registry as a national reference for United States multiple myeloma patients","volume":"9","author":"Ailawadhi","year":"2020","journal-title":"Cancer Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1182\/blood-2024-201794","article-title":"How much has the overall survival of multiple myeloma patients improved after the incorporation of new drugs in the first line of treatment in real-world experience (RWE)?","volume":"144","author":"Ortega","year":"2024","journal-title":"Blood"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/16\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:37:20Z","timestamp":1767191840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["curroncol33010016"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33010016","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]}}}